Pluristem Therapeutics Inc.  

(Public, NASDAQ:PSTI)   Watch this stock  
Find more results for psti
+0.08 (3.02%)
May 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.64 - 2.76
52 week 2.32 - 3.78
Open 2.70
Vol / Avg. 54,310.00/112,259.00
Mkt cap 193.95M
P/E     -
Div/yield     -
EPS -0.41
Shares 71.04M
Beta 0.68
Inst. own 2%
Apr 15, 2015
Pluristem Therapeutics Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6573.68% -7106.07%
Operating margin -6632.63% -7348.28%
EBITD margin - -6987.34%
Return on average assets -41.01% -37.84%
Return on average equity -48.72% -45.04%
Employees 142 -
CDP Score - -


Building #20 MATAM Advanced Technology Park
HAIFA, 31905
+972-74-7108600 (Phone)
+972-74-7108765 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotechnology company. Pluristem uses placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. Pluristem�s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells are a cell therapy product defined as mesenchymal-like adherent stromal cells (ASCs) derived from full term human placentas. Pluristem manufactures placenta-based cell products using a 3D bioreactor. Pluristem is pursuing multiple indications including Cardiovascular, Orthopedic, Pulmonary and Hematological diseases as well as preeclampsia. Through Pluristem�s in-house manufacturing facility the Company produces homogeneous, clinical-grade cells.

Officers and directors

Zami Aberman Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Yaky Yanay CPA President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Boaz Gur-Lavie Chief Financial Officer, Secretary
Age: 41
Bio & Compensation  - Reuters
Doron Shorrer CPA Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Moria Kwiat Director
Age: 35
Bio & Compensation  - Reuters
Hava Meretzki Director
Age: 46
Bio & Compensation  - Reuters
Israel Ben-Yoram Independent Director
Age: 54
Bio & Compensation  - Reuters
Issac Braun Independent Director
Age: 62
Bio & Compensation  - Reuters